Here's a recent study in a healthcare setting showing 73% reduction in infections: https://www.ncbi.nlm...les/PMC8405705/
Another healthcare study showing, ironically, 73% reduction in infections: https://pubmed.ncbi....h.gov/33592050/
In vitro testing showing 5000-fold decrease in activity when SARS-CoV-2 is exposed to ivermectin: https://pubmed.ncbi....h.gov/32251768/
RCT as a treatment showing 25% reduction in time to symptom clearance: https://pubmed.ncbi....h.gov/33278625/
Meta-review of ivermectin trials for COVID, this one summarizes quite a few studies up through middle/end of last year: https://www.ncbi.nlm...les/PMC8354804/
Recently, the WHO has commissioned a meta-analysis  to assess the clinical efficacy of ivermectin through the ACC Accelerator Program. The meta-analysis included 18 randomized controlled trials (RCTs) that evaluated doses up to 0.6 mg/kg of ivermectin, and conducted on a total of 2,282 RT-PCR positive patients (both, inpatients and outpatients), with mild to severe COVID-19 symptoms. Across six trials assessing the efficacy in survival in 1,255 patients, 14 of 658 patients (2.1%) died in the ivermectin arm versus 57 of 597 patients who died in the control arm (9.5%).
A real-time meta-analysis of 53 studies  conducted over a total sample of 17,582 patients with COVID-19 disease, assessing 27 RCTs, and 26 observational studies, described that all the studies included in the analysis reported positive effects.
According to a recent meta-analysis based on 18 randomized controlled treatment trials of ivermectin in COVID-19, mortality, time to clinical recovery, and time to viral clearance were lower in patients treated with this drug (33). In other meta-analysis analysing mortality in 28 clinical trials, mortality was also lower in the ivermectin arm versus non-ivermectin arm (OR 0.39, 95% CI 0.22-0.70) .
In a multicentre case-control study  of 280 hospitalized patients, ivermectin administered in a single dose of 150 µg/kg to patients diagnosed with SARS-CoV-2 infection, achieved a significant reduction in intrahospital mortality in those patients treated with the drug (1.4% versus 8.5% (ivermectin versus non-ivermectin; Hazard Ratio (HR) 0.20, 95% CI: 0.11 to 0.37, p<0.0001)
There's more in the paper. Or, you can wait for the big NIH-run trial that's underway.
My understanding is that at worst it does no harm (when dosed properly) and it ~might~ help. Paxlovid would be the better option tho since it is Covid specific
That's the thing, the downside is very minimal and there's a shitload of decent studies in its favor. The risk-reward definitely seems to lean towards taking it if you get COVID.
Edited by 3rd party JKor, 26 January 2022 - 09:07 PM.